Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
Fabio Venturella, Giulia Cancellieri, Marco Giammanco, Anna Maria Almerico, Igor Daniele Aleo, Anastasia Valentina Liga, et al. (2023). Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab. JOURNAL OF BIOLOGICAL RESEARCH, 96, 32-35 [10.4081/jbr.2023.11027].
Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab
Fabio Venturella;Giulia Cancellieri;Marco Giammanco;Anna Maria Almerico;Igor Daniele Aleo;Francesca Mortillaro;
2023-01-01
Abstract
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.File | Dimensione | Formato | |
---|---|---|---|
JBiolRes2023_96_1_11027.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.